Table of Content

Open Access iconOpen Access

REVIEW

crossmark

Is autophagy induction by PARP inhibitors a target for therapeutic benefit?

AHMED M. ELSHAZLY1,2, TUONG VI V. NGUYEN1, DAVID A. GEWIRTZ1,*

1 Department of Pharmacology and Toxicology, Virginia Commonwealth University, Massey Cancer Center, Richmond, VA, 23298, USA
2 Department of Pharmacology and Toxicology, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, 33516, Egypt

* Corresponding Author: DAVID A. GEWIRTZ. Email: email

Oncology Research 2022, 30(1), 1-12. https://doi.org/10.32604/or.2022.026459

Abstract

PARP inhibitors have proven to be effective in conjunction with conventional therapeutics in the treatment of various solid as well as hematologic malignancies, particularly when the tumors are deficient in DNA repair pathways. However, as the case with other chemotherapeutic agents, their effectiveness is often compromised by the development of resistance. PARP inhibitors have consistently been reported to promote autophagy, a process that maintains cellular homeostasis and acts as an energy source by the degradation and reutilization of damaged subcellular organelles and proteins. Autophagy can exhibit different functional properties, the most prominent being cytoprotective. In addition, both cytotoxic and non-protective functions forms have also been identified. In this review, we explore the available literature regarding the different roles of autophagy in response to clinically-used PARP inhibitors, highlighting the possibility of targeting autophagy as an adjuvant therapy to potentially increase the effectiveness of PARP inhibition and to overcome the development of resistance.

Keywords


Cite This Article

APA Style
ELSHAZLY, A.M., NGUYEN, T.V.V., GEWIRTZ, D.A. (2022). Is autophagy induction by PARP inhibitors a target for therapeutic benefit?. Oncology Research, 30(1), 1-12. https://doi.org/10.32604/or.2022.026459
Vancouver Style
ELSHAZLY AM, NGUYEN TVV, GEWIRTZ DA. Is autophagy induction by PARP inhibitors a target for therapeutic benefit?. Oncol Res. 2022;30(1):1-12 https://doi.org/10.32604/or.2022.026459
IEEE Style
A.M. ELSHAZLY, T.V.V. NGUYEN, and D.A. GEWIRTZ, “Is autophagy induction by PARP inhibitors a target for therapeutic benefit?,” Oncol. Res., vol. 30, no. 1, pp. 1-12, 2022. https://doi.org/10.32604/or.2022.026459



cc Copyright © 2022 The Author(s). Published by Tech Science Press.
This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 1715

    View

  • 739

    Download

  • 0

    Like

Share Link